title: Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.
abstract: Adeno-associated viral (AAV) vectors 2 and 8 have been used in clinical trials for patients with hemophilia, and data suggest that the capsid-specific CD8⁺ T cell response has had a negative impact on therapeutic success. To date the pattern of capsid cross-presentation from AAV2 and AAV8 transduction in vivo has not been elucidated. Previously, we have demonstrated that an engineered AAV2 virus carrying the immune-dominant SIINFEKL peptide in the capsid backbone was indistinguishable from wild type with respect to titer, tropism, and the ability to induce capsid-specific CD8⁺ T cell responses in vivo. In this study, we used the same strategy to engineer an AAV8 vector and demonstrated that antigen from SIINFEKL peptide-integrated AAV8 capsid was effectively presented via either plasmid transfection or AAV8 transduction in vitro. The tissue tropism and transgene expression kinetics of the engineered AAV8 vector in vivo were identical to that of wild-type AAV8. Animal studies show that capsid antigen presentation from AAV transduction was dose dependent, and more importantly, the proliferation of capsid-specific CD8⁺ T cells had similar kinetics (detectable before 30 days and undetectable after 40 days) for both AAV2 and AAV8 vectors. Elucidation of the kinetics of capsid antigen presentation from AAV transduction by various serotypes provides new insight into the potential impact CD8⁺ T cells can have during clinical trials and may help with rational design of effective strategies to prevent capsid-specific CD8⁺ T cell-mediated elimination of AAV-transduced target cells.
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: He
authors.forename: Marc S
authors.initials: MS
authors.lastname: Weinberg
authors.forename: Matt
authors.initials: M
authors.lastname: Hirsch
authors.forename: Mark C
authors.initials: MC
authors.lastname: Johnson
authors.forename: Roland
authors.initials: R
authors.lastname: Tisch
authors.forename: R Jude
authors.initials: RJ
authors.lastname: Samulski
authors.forename: Chengwen
authors.initials: C
authors.lastname: Li
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000235:genetics / Q000276:immunology*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D002986:Clinical Trials as Topic; D045142:Cross-Priming / Q000235:genetics / Q000276:immunology; D000229:Dependovirus / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007700:Kinetics; D008297:Male; D012703:Serotyping; D014161:Transduction, Genetic
chemical_list: D036022:Capsid Proteins
references.citation: J Virol. 1998 Mar;72(3):2224-32
references.pmid: 9499080
references.citation: Mol Ther. 2008 Feb;16(2):280-9
references.pmid: 18059373
references.citation: Lancet. 2009 Nov 7;374(9701):1597-605
references.pmid: 19854499
references.citation: J Clin Invest. 2013 Mar;123(3):1390-401
references.pmid: 23454772
references.citation: Gene Ther. 2001 Aug;8(16):1248-54
references.pmid: 11509958
references.citation: Gene Ther. 2012 Apr;19(4):404-10
references.pmid: 21850052
references.citation: Mol Ther. 2006 Jan;13(1):77-87
references.pmid: 16219492
references.citation: N Engl J Med. 2011 Dec 22;365(25):2357-65
references.pmid: 22149959
references.citation: Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14258-63
references.pmid: 21844342
references.citation: Hum Gene Ther. 2007 Mar;18(3):185-94
references.pmid: 17324107
references.citation: Mol Ther. 2006 Feb;13(2):260-9
references.pmid: 16324888
references.citation: Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10770-4
references.pmid: 19541644
references.citation: Nat Med. 2006 Mar;12(3):342-7
references.pmid: 16474400
references.citation: Gene Ther. 2003 Dec;10(26):2112-8
references.pmid: 14625565
references.citation: Mol Ther. 2006 Apr;13(4):823-8
references.pmid: 16473554
references.citation: Blood. 2009 Sep 3;114(10):2077-86
references.pmid: 19506302
references.citation: J Virol. 1998 Feb;72(2):1438-45
references.pmid: 9445046
references.citation: J Virol. 2009 Jul;83(13):6817-24
references.pmid: 19369348
references.citation: Mol Ther. 2010 Mar;18(3):643-50
references.pmid: 19953081
references.citation: J Immunol. 2007 Feb 15;178(4):2396-406
references.pmid: 17277146
references.citation: J Virol. 2007 Jul;81(14):7540-7
references.pmid: 17475652
references.citation: Mol Ther. 2011 Mar;19(3):536-46
references.pmid: 21157435
references.citation: Nat Med. 2006 Aug;12(8):967-71
references.pmid: 16845388
references.citation: N Engl J Med. 2008 May 22;358(21):2240-8
references.pmid: 18441370